1
Clinical Trials associated with Expanded NK Cells(New Approaches to Neuroblastoma Therapy) / Active, not recruitingPhase 1 A Phase I Dose Escalation Study of Autologous Expanded Natural Killer (NK) Cells for Immunotherapy of Relapsed Refractory Neuroblastoma With Dinutuximab +/- Lenalidomide
This NANT trial will determine the maximum tolerated dose (MTD) of autologous expanded natural killer (NK) cells when combined with standard dosing of dinutuximab and will assess the feasibility of adding lenalidomide at the recommended Phase II dose of the expanded NK cells with dinutuximab, for treatment of children with refractory or recurrent neuroblastoma.
100 Clinical Results associated with Expanded NK Cells(New Approaches to Neuroblastoma Therapy)
100 Translational Medicine associated with Expanded NK Cells(New Approaches to Neuroblastoma Therapy)
100 Patents (Medical) associated with Expanded NK Cells(New Approaches to Neuroblastoma Therapy)
100 Deals associated with Expanded NK Cells(New Approaches to Neuroblastoma Therapy)